Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019062251) ISOLATED RECOMBINANT ONCOLYTIC ADENOVIRUS, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOLATED RECOMBINANT ONCOLYTIC ADENOVIRUS IN MEDICATION FOR TREATMENT OF TUMOR AND/OR CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/062251 International Application No.: PCT/CN2018/094264
Publication Date: 04.04.2019 International Filing Date: 03.07.2018
IPC:
C12N 7/01 (2006.01) ,A61K 35/761 (2015.01) ,C12N 15/861 (2006.01) ,C12N 15/113 (2010.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7
Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01
Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
[IPC code unknown for A61K 35/761]
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79
Vectors or expression systems specially adapted for eukaryotic hosts
85
for animal cells
86
Viral vectors
861
Adenoviral vectors
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
113
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
杭州康万达医药科技有限公司 HANGZHOU CONVERD CO., LTD. [CN/CN]; 中国浙江省杭州市 余杭区仓前街道余杭塘路2959号4幢7层 7th Floor, Building #4, 2959 Yuhangtang Road, Yuhang District Hangzhou, Zhejiang 311121, CN
Inventors:
绳纪坡 SHENG, Jipo; CN
傅瑾 FU, Jin; CN
赵荣华 ZHAO, Ronghua; CN
秦云 QIN, Yun; CN
陈霖 CHEN, Lin; CN
康三毛 KANG, Sanmao; CN
胡放 HU, Fang; CN
Agent:
北京天昊联合知识产权代理有限公司 TEE & HOWE INTELLECTUAL PROPERTY ATTORNEYS; 中国北京市 东城区建国门内大街28号民生金融中心D座10层樊晓焕 FAN, Xiaohuan 10th Floor, Tower D, Minsheng Financial Center 28 Jianguomennei Avenue Dongcheng District, Beijing 100005, CN
Priority Data:
201710899291.628.09.2017CN
Title (EN) ISOLATED RECOMBINANT ONCOLYTIC ADENOVIRUS, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOLATED RECOMBINANT ONCOLYTIC ADENOVIRUS IN MEDICATION FOR TREATMENT OF TUMOR AND/OR CANCER
(FR) ADÉNOVIRUS ONCOLYTIQUE RECOMBINÉ ISOLÉ, COMPOSITION PHARMACEUTIQUE, ET APPLICATION DE L'ADÉNOVIRUS ONCOLYTIQUE RECOMBINÉ ISOLÉ DANS UN MÉDICAMENT POUR LE TRAITEMENT D'UNE TUMEUR ET/OU D'UN CANCER
(ZH) 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
Abstract:
(EN) The present invention provides an isolated recombinant oncolytic adenovirus, a pharmaceutical composition, and an application of the isolated recombinant oncolytic adenovirus in a medication for treatment of a tumor and/or cancer. The recombinant oncolytic adenovirus is a replication-selective oncolytic adenovirus, and a coding sequence of exogenous shRNA capable of inhibiting PDL1 expression in tumor cells is integrated in a genome of the recombinant oncolytic adenovirus. The replication capability of the virus in normal primary cells is much lower than the replication capability of the virus in tumor cells; moreover, the expressed shPDL1 can significantly reduce the high PDL1 protein expression level in the tumor cells; thus, the oncolytic killing effect of the oncolytic virus and the anti-tumor immunostimulatory effect of immune cells can produce a synergistic effect.
(FR) La présente invention concerne un adénovirus oncolytique recombiné isolé, une composition pharmaceutique, et une application de l'adénovirus oncolytique recombiné isolé dans un médicament pour le traitement d'une tumeur et/ou d'un cancer. L'adénovirus oncolytique recombiné est un adénovirus oncolytique à réplication sélective, et une séquence codante de shARN exogène capable d'inhiber l'expression de PDL1 dans des cellules tumorales est intégrée dans un génome de l'adénovirus oncolytique recombiné. La capacité de réplication du virus dans des cellules primaires normales est bien inférieure à la capacité de réplication du virus dans des cellules tumorales ; de plus, le shPDL1 exprimé peut réduire significativement le niveau d'expression élevé de la protéine PDL1 dans les cellules tumorales ; ainsi, l'effet létal oncolytique du virus oncolytique et l'effet immunostimulateur anti-tumoral des cellules immunitaires peuvent produire un effet synergique.
(ZH) 本发明提供了分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途。所述重组溶瘤腺病毒为选择复制型溶瘤腺病毒,并且该重组溶瘤腺病毒的基因组中整合有能够在肿瘤细胞中抑制PDL1表达的外源shRNA的编码序列。该病毒在正常原代细胞中的复制能力远远低于其在肿瘤细胞中的复制能力,并且所表达的shPDL1能够显著降低肿瘤细胞内高表达的PDL1蛋白水平,从而使溶瘤病毒的溶瘤杀伤作用和免疫细胞的抗肿瘤免疫刺激作用产生协同效果。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)